Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis...
17 KB (1,245 words) - 14:04, 2 September 2024
demonstrated that bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis. "Bimzelx APMDS"...
11 KB (656 words) - 16:11, 7 August 2024
well as the IL-12/IL-23 inhibitor ustekinumab, the IL-17A inhibitor secukinumab, and the IL-23 inhibitor risankizumab. Biologics may increase the risk...
32 KB (3,440 words) - 01:34, 28 October 2024
changes. In May 2023, the European Commission (EC) approved Cosentyx (secukinumab) for active moderate to severe hidradenitis suppurativa in adults. Other...
59 KB (5,870 words) - 01:27, 13 October 2024
2021-08-15. Retrieved 2021-10-01. "Study: Guselkumab More Effective Than Secukinumab in Certain Subpopulations". Dermatology Times. 3 September 2021. Retrieved...
25 KB (1,860 words) - 04:49, 26 July 2024
(INN) Seconal secoverine (INN) Secran Secreflo secretin (INN) Sectral secukinumab (INN) securinine (INN) Sedapap sedecamycin (INN) Seffin seganserin (INN)...
7 KB (370 words) - 22:19, 30 September 2024
Woessner, Ralph; Pieber, Thomas Rudolf; Cheng, Yi (November 23, 2015). "Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated...
29 KB (3,048 words) - 04:58, 2 November 2024
severe cases of psoriasis. There is also some evidence to support use of secukinumab, brodalumab, guselkumab, certolizumab, and ustekinumab. In general, anti-IL17...
116 KB (13,061 words) - 15:20, 6 November 2024
this class target IL-17, an important part of the inflammatory system: secukinumab and ixekizumab. They are often considered in cases where TNFi drugs are...
56 KB (5,992 words) - 03:13, 19 October 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
23 KB (1,813 words) - 18:30, 5 November 2024
antibodies available or studied as injector pens include adalimumab, secukinumab, and alirocumab. CGRP antagonists which are monoclonal antibodies, used...
27 KB (3,140 words) - 17:25, 26 July 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
15 KB (1,089 words) - 18:39, 16 October 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
22 KB (2,581 words) - 20:03, 21 June 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
38 KB (3,075 words) - 05:52, 21 October 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
12 KB (1,289 words) - 19:20, 4 December 2023
(uncomplicated) Comtan (entacapone) Parkinson's disease 530 2012 −14% Cosentyx (secukinumab) Psoriasis Diovan (valsartan) Hypertension 4,417 2012 −22% Entresto...
144 KB (12,146 words) - 09:25, 31 October 2024
CD20 on B-cell surface bDMARD sarilumab IL-6 receptor antagonist bDMARD secukinumab IL-17 inhibitor bDMARD sulfasalazine (SSZ) Suppression of IL-1 & TNF-alpha...
10 KB (854 words) - 06:50, 2 November 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
24 KB (2,084 words) - 05:31, 21 October 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
5 KB (286 words) - 05:02, 7 September 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
12 KB (1,323 words) - 14:55, 7 September 2024
Netakimab Olokizumab Rilonacept Risankizumab Sarilumab Satralizumab Secukinumab Siltuximab Sirukumab Spesolimab Tildrakizumab Tocilizumab Ustekinumab...
7 KB (299 words) - 13:45, 27 April 2024
L04AC07 Tocilizumab L04AC08 Canakinumab L04AC09 Briakinumab L04AC10 Secukinumab L04AC11 Siltuximab L04AC12 Brodalumab L04AC13 Ixekizumab L04AC14 Sarilumab...
3 KB (367 words) - 15:37, 25 January 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
26 KB (3,273 words) - 08:48, 14 October 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
14 KB (1,147 words) - 07:33, 11 August 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
14 KB (1,578 words) - 23:52, 11 October 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
63 KB (7,473 words) - 05:58, 16 October 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
16 KB (1,451 words) - 18:24, 2 August 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
19 KB (2,293 words) - 11:05, 8 March 2024
neuromyelitis optica Satumomab pendetide mab mouse TAG-72 cancer (diagnosis) Secukinumab Cosentyx mab human IL-17A Y uveitis, rheumatoid arthritis psoriasis Selicrelumab...
137 KB (4,083 words) - 21:25, 19 October 2024
(interleukin 25), F) Antibodies: Brodalumab Ixekizumab Perakizumab Remtolumab Secukinumab Vunakizumab IL-18 Agonists: Iboctadekin Interleukin 18 Interleukin 37...
15 KB (1,511 words) - 05:31, 2 July 2024